FAKTOR OPTIONSSCHEIN - PTC THERAPEUTICS Stock

Certificat

DE000GG8FDD5

Real-time BOERSE MUENCHEN 02:26:22 2024-07-05 pm EDT
23.93 EUR +5.93% Intraday chart for FAKTOR OPTIONSSCHEIN - PTC THERAPEUTICS
Current month-7.96%
1 month+96.95%
Date Price Change
24-07-05 23.93 +5.93%
24-07-04 22.59 -6.38%
24-07-03 24.13 -3.40%
24-07-02 24.98 +12.88%
24-07-01 22.13 -14.88%

Real-time BOERSE MUENCHEN

Last update July 05, 2024 at 02:26 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying PTC THERAPEUTICS, INC.
Issuer Goldman Sachs
WKN GG8FDD
ISINDE000GG8FDD5
Date issued 2024-05-21
Strike 37.12 $
Maturity Unlimited
Parity 0.26 : 1
Emission price 10.27
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 26.1
Lowest since issue 11.26
Spread 0.5
Spread %2.17%

Company Profile

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Sector
-
More about the company

Ratings for PTC Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: PTC Therapeutics, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
30.93 USD
Average target price
38.75 USD
Spread / Average Target
+25.28%
Consensus